Plasma levels of soluble receptor for advanced glycation end products (sRAGE) and proinflammatory ligand for RAGE (EN-RAGE) are associated with carotid atherosclerosis in patients with peritoneal dialysis

Atherosclerosis

Volumn 220, Issue 1, 2012, Pages 208-214

  Kim, Jwa Kyung ^a   Park, Sungha ^b   Lee, Mi Jung ^b   Song, Young Rim ^a   Han, Seung Hyeok ^b   Kim, Sung Gyun ^a   Kang, Shin Wook ^b   Choi, Kyu Hun ^b   Kim, Hyung Jik ^a   Yoo, Tae Hyun ^b  

^a Hallym University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Carotid intima media thickness (cIMT); EN RAGE; Peritoneal dialysis; Soluble receptor for advanced glycation end products (sRAGE)

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ADVANCED GLYCATION END PRODUCT RECEPTOR BINDING PROTEIN; BINDING PROTEIN; C REACTIVE PROTEIN; INTERLEUKIN 6; UNCLASSIFIED DRUG;

ABDOMINAL AORTA; ABDOMINAL RADIOGRAPHY; ADULT; ARTERIAL WALL THICKNESS; ARTERY CALCIFICATION; ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; ECHOGRAPHY; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PERITONEAL DIALYSIS; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENESCENCE;

ADULT; AGED; ANALYSIS OF VARIANCE; AORTA, ABDOMINAL; AORTIC DISEASES; AORTOGRAPHY; BIOLOGICAL MARKERS; CAROTID ARTERY DISEASES; CAROTID INTIMA-MEDIA THICKNESS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INFLAMMATION MEDIATORS; KIDNEY FAILURE, CHRONIC; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PERITONEAL DIALYSIS; RECEPTORS, IMMUNOLOGIC; REPUBLIC OF KOREA; RISK ASSESSMENT; RISK FACTORS; S100 PROTEINS; VASCULAR CALCIFICATION;

EID: 84155160626     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.07.115     Document Type: Article

References (30)

1. Collins A.J., Foley R.N., Herzog C., et al. Excerpts from the US Renal Data System 2009 Annual Data Report. Am J Kidney Dis 2010, 55. p. S1-S420/A6-A7.
2. Mahajan N., Malik N., Bahl A., Dhawan V. Receptor for advanced glycation end products (RAGE)and its inflammatory ligand EN-RAGE in non-diabetic subjects with pre-mature coronary artery disease. Atherosclerosis 2009, 207:597-602.
3. Park S., Yoon S.J., Tae H.J., Shim C.Y. RAGE and cardiovascular disease. Front Biosci 2011, 16:486-497.
4. Chen Y.S., Yan W., Geczy C.L., Brown M.A., Thomas R. Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis. Arthritis Res Ther 2009, 11:R39.
5. Emanuele E., D'Angelo A., Tomaino C., et al. Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. Arch Neurol 2005, 62:1734-1736.
6. Taguchi A., Blood D.C., del Toro G., et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000, 405:354-360.
7. Schmidt A.M., Yan S.D., Yan S.F., Stern D.M. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001, 108:949-955.
8. Kalousova M., Hodkova M., Kazderova M., et al. Soluble receptor for advanced glycation end products in patients with decreased renal function. Am J Kidney Dis 2006, 47:406-411.
9. Basta G., Leonardis D., Mallamaci F., et al. Circulating soluble receptor of advanced glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease. Kidney Int 2010, 77:225-231.
10. Basta G., Sironi A.M., Lazzerini G., et al. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J Clin Endocrinol Metab 2006, 91:4628-4634.
11. Park L., Raman K.G., Lee K.J., et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation end products. Nat Med 1998, 4:1025-1031.
12. Flyvbjerg A., Denner L., Schrijvers B.F., et al. Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice. Diabetes 2004, 166-172.
13. Wendt T., Harja E., Bucciarelli L., et al. RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. Atherosclerosis 2006, 85:70-77.
14. Mori Y., Kosaki A., Kishimoto N., et al. Increased plasma S100A12 (EN-RAGE) levels in hemodialysis patients with atherosclerosis. Am J Nephrol 2009, 9:18-24.
15. Kosaki A., Hasegawa T., Kimura T., et al. Increased plasma S100A12 (EN-RAGE) levels in patients with type 2 diabetes. J Clin Endocrinol Metab 2004, 9:5423-5428.
16. Nakashima A., Carrero J.J., Qureshi A.R., et al. Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in hemodialysis patients. Clin J Am Soc Nephrol 2010, 5:213-2219.
17. Shiotsu Y., Mori Y., Nishimura M., et al. Plasma S100A12 level is associated with cardiovascular disease in hemodialysis patients. Clin J Am Soc Nephrol 2011, 718-723.
18. Zeier M., Schwenger V., Deppisch R., et al. Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation?. Kidney Int 2003, 298-305.
19. Williams J.D., Topley N., Craig K.J., et al. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004, 6:408-418.
20. Stompor T., Krasniak A., Sulowicz W., et al. Changes in common carotid artery intima-media thickness over 1 year in patients on peritoneal dialysis. Nephrol Dial Transplant 2005, 20:404-412.
21. Lemos M.M., Jancikic A.D., Sanches F.M., et al. Intima-media thickness is associated with inflammation and traditional cardiovascular risk factors in non-dialysis-dependent patients with chronic kidney disease. Nephron Clin Pract 2010, 115:c189-c194.
22. Simon A., Megnien J.L., Chironi G. The value of carotid intima-media thickness for predicting cardiovascular risk. ArteriosclerThrombVasc Biol 2010, 30:182-185.
23. Verbeke F., Van Biesen W., Honkanen E., et al. Prognostic value of aortic stiffness and calcification for cardiovascular events and mortality in dialysis patients: outcome of the calcification outcome in renal disease (CORD) study. Clin J Am Soc Nephrol 2011, 6:153-159.
24. Koyama H., Nishizawa Y. AGEs/RAGE in CKD: irreversible metabolic memory road toward CVD?. Eur J Clin Invest 2010, 40:623-635.
25. Franke S., Muller A., Sommer M., Busch M., Kientsch-Engel R., Stein G. Serum levels of total homocysteine, homocysteine metabolites and of advanced glycation end-products (AGEs) in patients after renal transplantation. Clin Nephrol 2003, 59:88-97.
26. Gohda T., Tanimoto M., Moon J.Y., et al. Increased serum endogenous secretory receptor for advanced glycation end-product (esRAGE) levels in type 2 diabetic patients with decreased renal function. Diabetes Res Clin Pract 2008, 81:196-201.
27. Tanikawa T., Okada Y., Tanikawa R., Tanaka Y. Advanced glycation end products induce calcification of vascular smooth muscle cells through RAGE/p38 MAPK. J Vasc Res 2009, 46:572-580.
28. Mahajan N., Bahl A., Dhawan V. C-reactive protein (CRP) up-regulates expression of receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in THP-1 cells: inhibitory effects of atorvastatin. Int J Cardiol 2010, 142:273-278.
29. Gawdzik J., Mathew L., Kim G., Puri T.S., Hofmann Bowman M.A. Vascular remodeling and arterial calcification are directly mediated by S100A12 (EN-RAGE) in chronic kidney disease. Am J Nephrol 2011, 33:250-259.
30. Towler D.A. Vascular calcification: it's all the RAGE!. Arterioscler Thromb Vasc Biol 2011, 31:237-239.